MedTrace Logo

Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients

NCT03149900 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-08-16

No results posted yet for this study

Summary

To identify possible genetic associations of clinical response to anti-IL-17A (Secukinumab) treatment in psoriasis using a combined gene association study and gene expression analysis.

To investigate the influence of IL-17A on the cutaneous microbial flora and to analyse cutaneous antimicrobial peptide expression in the skin of patients with psoriasis prior to, and during, treatment with Secukinumab to determine the extent to which the microbial flora is associated with response to treatment, as determined by the PASI75, PASI90, PGA- and DLQI improvement.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

Secukinumab

See Arm Description

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Diamant Thaci

    lead OTHER

Principal Investigators

  • Diamant Thaci, Prof. Dr. · University of Luebeck

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2019-07-25
Completion
2019-07-25

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03149900 on ClinicalTrials.gov